10th Workshop on Recent Issues in Bioanalysis (WRIB)
Visit Q2 Solutions at Booth 20, and join Paul Rhyne and Barry Jones for their training sessions
About This EventVisit Q2 Solutions at booth 20 to learn more about how we work with customers to solve some of today’s most challenging bioanalytical and ADME issues. We will also be hosting two presentations as part of the WRIB training courses.
Speaker: Paul Rhyne
Title: Current Best practices in Commercial Kits Evaluation/Validation for Biomarkers Assays
Training Course F-1 - 8am to 5pm, Friday April 22, 2016 - BIOMARKERS from Discovery to Development / from Exploratory to Confirmatory: Method Development, Performance Evaluation and Validation by LBA, Flow Cytometry and LCMS in GLP/CLIA
Speaker: Barry Jones
Title: Robustness of the Hybrid LBA/LCMS Assays in a Regulated Environment
Training Course M-2 for LCMS scientists - 8am to 5pm, Monday April 18, 2016 - The Latest Advancements in Large Molecules Method Development & Validation by LCMS/HRMS from Discovery to Regulated Bioanalysis
We look forward to meeting you in Orlando, FL.
Scientific Director, Bioanalytical and ADME Immunoassay Services
Dr. Paul W. Rhyne leads a bioanalytical group for Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Rhyne has more than 15 years of scientific leadership experience in laboratory operations, clinical biomarkers, large molecule PK analysis and Immunogenicity assessment. He obtained his Ph.D. at the University of Tennessee Memphis and completed three years of post-doctoral studies at St. Jude Children’s Research Hospital. Dr. Rhyne was an Associate Director at Bristol-Myers Squibb Company, a Senior Director at Tandem laboratories, and has held many senior leadership positions at Upstate Biotechnology and Amplistar Inc. A noted industry expert in clinical biomarkers and large molecule bioanalytical analysis, he has published many scientific publications in peer-reviewed journals. Dr. Rhyne is an active member of the American Association of Pharmaceutical Scientists, including serving on programming committees, a steering committee for a translational biomarker focus group, and as chair of the biomarker discussion group.